세계의 운동완만 시장 보고서(2025년)

Bradykinesia Global Market Report 2025

US $ 4,490 ￦ 6,516,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,419,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,322,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

운동완만 시장 규모는 향후 수년간 급성장할 것으로 예측됩니다. 2029년에는 CAGR 13.4%로 성장할 전망이며, 56억 4,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 전 세계 파킨슨병 유병률 상승, 신경질환 발생률 증가, 신경변성 질환에 쉽게 걸릴 수 있는 고령화, 운동완만의 인지도 향상 및 조기 발견, 신흥 시장에서 진단능력 강화 등에 기인할 것으로 보입니다. 이 기간에 예상되는 주요 동향으로는 신경 자극 기술의 발전, 혁신적인 약물 전달 시스템의 출현, 동작 추적 및 증상 모니터링을 위한 웨어러블 디바이스의 채택, 원격 의료 및 신경학 원격 진찰의 확대, 운동 기능 장애의 치료를 목적으로 한 유전자 치료의 개발 등을 들 수 있습니다.

신경질환의 유병률 상승은 향후 수년간 운동완만 시장의 성장을 견인할 것으로 예측됩니다. 이러한 질환은 뇌, 척수, 말초 신경에 영향을 미쳐 운동, 감각, 인지, 기타 신체 기능에 장애를 초래하는 병세입니다. 신경질환의 세계적 증가는 인구의 고령화가 주요 원인이며, 노화에 따른 뇌의 변화가 신경계 질환의 위험을 높이기 때문입니다. 신경질환의 대부분은 움직임의 둔화 및 저하와 관련되어 있기 때문에 운동완만을 포함한 운동기능장애에 대처하는 치료에 대한 수요가 높아지고 있습니다. 예를 들면, 2023년 1월, 미국을 거점으로 하는 옹호 단체인 미국 파킨슨병 협회(APDA)는 파킨슨병은 2030년까지 130만 명이 이환될 것으로 예상되며, 진단된 증례의 일관된 증가를 반영하고 있다고 보고했습니다. 따라서 신경질환의 이환율 증가는 운동완만 시장 확대에 크게 기여하게 됩니다.

운동완만 시장의 주요 기업은 정제를 삼키는 데 어려움을 겪고 있는 환자에게 보다 쉬운 투여를 제공하기 위해 설하 요법과 같은 혁신적인 솔루션의 개발을 선호합니다. 설하요법은 혀 밑에 약제를 놓는 것으로 점막을 통해 혈류에 빠르게 흡수되어 신속한 치료 효과를 얻을 수 있습니다. 예를 들면, 2023년 3월, 포르투갈에 본사를 둔 파킨슨병 치료를 전문으로 하는 BIAL은, 파킨슨병의 OFF 에피소드를 온디맨드로 관리하기 위한 KYNMOBI(아포모르핀염산염)를 발표했습니다. 이 OFF 에피소드는 표준적인 약제가 듣지 않게 되었을 때 운동완만, 진전, 경직 등의 증상이 재발 또는 악화되는 것을 특징으로 합니다. 아포모르핀 염산염의 설하 필름 제제는 혀 밑에서 녹기 때문에 즉효성이 있어 사용하기 쉬운 선택지입니다. 비에르고린계 도파민 아고니스트로서 급격한 운동 변동에 대한 대처를 돕고 일반적으로 인용성이 높으며 휴약기간 동안 보다 일관된 증상의 조절을 기재하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 운동완만 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 운동완만 시장 : 성장률 분석
• 세계의 운동완만 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 운동완만 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 운동완만 : 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 운동완만 시장 : 병용 요법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 단제요법
• 병용요법
• 세계의 운동완만 시장 : 질병 중증도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 파킨슨병의 초기 단계
• 진행기 파킨슨병
• 세계의 운동완만 시장 : 증상 관리별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 운동완만
• 떨림
• 경직
• 세계의 운동완만 시장 : 단제요법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 레보도파
• 도파민 작용제
• MAO-B 억제제
• 항콜린제
• 아만타딘
• 세계의 운동완만 시장 : 병용요법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 레보도파와 카르비도파
• 레보도파와 COMT 억제제
• 도파민 작용제와 MAO-B 억제제
• 레보도파와 MAO-B 억제제
• 트리플 테라피

제7장 지역별 및 국가별 분석

• 세계의 운동완만 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 운동완만 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

• 운동완만 시장 : 경쟁 구도
• 운동완만 시장 : 기업 프로파일
  • AbbVie Inc.
  • Novartis AG
  • Medtronic Plc
  • Eli Lilly and Company
  • Otsuka Pharmaceutical Co. Ltd.

제31장 기타 주요 기업 및 혁신 기업

• Biogen Inc.
• Eisai Co. Ltd.
• Kyowa Kirin Co. Ltd.
• Lundbeck AS
• Amneal Pharmaceuticals Inc.
• Orion Corporation
• Acadia Pharmaceuticals Inc.
• Acorda Therapeutics Inc.
• Denali Therapeutics Inc.
• Adamas Pharmaceuticals
• Impel NeuroPharma
• Annovis Bio Inc.
• BlueRock Therapeutics LLC
• NeuroDerm Ltd.
• Cerevance LLC

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 운동완만 시장(2029년) : 새로운 기회를 제공하는 국가
• 운동완만 시장(2029년) : 새로운 기회를 제공하는 부문
• 운동완만 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

Bradykinesia is characterized by a distinct slowness in starting and carrying out voluntary movements. It commonly appears as a decreased ability to perform quick, alternating motions or trouble completing everyday tasks that require motor coordination. Affected individuals may seem less spontaneous in their movements, with activities like walking, writing, or displaying facial expressions becoming noticeably slower.

The primary treatment approaches for bradykinesia include monotherapy and combination therapy. Monotherapy involves the administration of a single drug, most often a dopamine replacement or agonist, aimed at alleviating symptoms related to slowed movement. It is applied in both early and advanced stages of Parkinson's disease to manage symptoms such as bradykinesia, tremors, and muscle rigidity.

The bradykinesia market research report is one of a series of new reports from The Business Research Company that provides bradykinesia market statistics, including bradykinesia industry global market size, regional shares, competitors with a bradykinesia market share, detailed bradykinesia market segments, market trends and opportunities, and any further data you may need to thrive in the bradykinesia industry. This bradykinesia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bradykinesia market size has grown rapidly in recent years. It will grow from $3.00 billion in 2024 to $3.41 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth during the historical period can be attributed to the rising number of movement disorder clinics, the increasing burden of post-stroke motor complications, the prevalence of hereditary neurodegenerative diseases, a surge in clinical trials focused on bradykinesia-related treatments, and the expansion of healthcare infrastructure.

The bradykinesia market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The projected growth in the forecast period can be attributed to the global rise in Parkinson's disease prevalence, a growing incidence of neurological disorders, an aging population susceptible to neurodegenerative conditions, increased awareness and early detection of bradykinesia, and the enhancement of diagnostic capabilities in emerging markets. Key trends expected during this period include advancements in neurostimulation technologies, the emergence of innovative drug delivery systems, the adoption of wearable devices for motion tracking and symptom monitoring, the expansion of telehealth and remote neurology consultations, and the development of gene therapies aimed at treating motor dysfunction.

The rising prevalence of neurological disorders is expected to drive the growth of the bradykinesia market in the coming years. These disorders are medical conditions that impact the brain, spinal cord, or peripheral nerves, resulting in impairments in movement, sensation, cognition, or other bodily functions. The global increase in neurological disorders is largely attributed to an aging population, as age-related changes in the brain heighten the risk of nervous system diseases. As many neurological conditions are associated with slowed or reduced movement, there is a growing demand for treatments that address motor dysfunction, including bradykinesia. For example, in January 2023, the American Parkinson Disease Association (APDA), a U.S.-based advocacy group, reported that Parkinson's disease is expected to affect 1.3 million individuals by 2030, reflecting a consistent rise in diagnosed cases. Hence, the growing incidence of neurological disorders will significantly contribute to the expansion of the bradykinesia market.

Leading companies in the bradykinesia market are prioritizing the development of innovative solutions, such as sublingual therapies, to provide easier administration for patients who struggle with swallowing pills. Sublingual therapies involve placing the medication under the tongue, allowing it to be quickly absorbed into the bloodstream through the mucous membranes for a rapid therapeutic effect. For example, in March 2023, BIAL, a Portugal-based company specializing in Parkinson's disease treatments, introduced KYNMOBI (apomorphine hydrochloride) for the on-demand management of OFF episodes in Parkinson's disease. These OFF episodes are characterized by the return or worsening of symptoms like bradykinesia, tremor, and rigidity when standard medications lose effectiveness. The sublingual film form of apomorphine hydrochloride provides a fast-acting, easy-to-use option that dissolves beneath the tongue. As a non-ergoline dopamine agonist, it aids in managing sudden motor fluctuations and is generally well-tolerated, offering more consistent control of symptoms during OFF periods.

In October 2023, AbbVie Inc., a U.S.-based biopharmaceutical company, acquired Mitokinin for an undisclosed sum. Post-acquisition, the program gained support from AbbVie's Neuroscience and External Innovation teams, which contributed valuable expertise and resources to advance the initiative toward investigational new drug (IND)-enabling studies. Mitokinin is a U.S.-based company specializing in treatments for bradykinesia.

Major players in the bradykinesia market are AbbVie Inc., Novartis AG, Medtronic Plc, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Lundbeck AS, Amneal Pharmaceuticals Inc., Orion Corporation, Acadia Pharmaceuticals Inc., Acorda Therapeutics Inc., Denali Therapeutics Inc., Adamas Pharmaceuticals, Impel NeuroPharma, Annovis Bio Inc., BlueRock Therapeutics LLC, NeuroDerm Ltd., Cerevance LLC, Sage Therapeutics, Anavex Life Sciences Corp., Inhibikase Therapeutics Inc.

North America was the largest region in the bradykinesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bradykinesia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bradykinesia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bradykinesia market consists of revenues earned by entities by providing services such as motor function assessment, digital monitoring, rehabilitation therapy programs, neurofeedback, and cognitive training. The market value includes the value of related goods sold by the service provider or included within the service offering. The bradykinesia market also includes sales of wearable motion trackers, smart gloves, home-based mobility aids, posture and movement correction devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bradykinesia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bradykinesia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bradykinesia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bradykinesia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Combination Therapy: Mono-Therapy; Combination Therapy
• 2) By Disease Severity: Early-Stage Parkinson's; Advanced-Stage Parkinson's
• 3) By Symptom Management: Bradykinesia; Tremors; Rigidity
• Subsegments:
• 1) By Mono-Therapy: Levodopa; Dopamine Agonists; MAO-B Inhibitors; Anticholinergics; Amantadine
• 2) By Combination Therapy: Levodopa And Carbidopa; Levodopa And COMT Inhibitors; Dopamine Agonists And MAO-B Inhibitors; Levodopa And MAO-B Inhibitors; Triple Therapy
• Companies Mentioned: AbbVie Inc.; Novartis AG; Medtronic Plc; Eli Lilly and Company; Otsuka Pharmaceutical Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bradykinesia Market Characteristics

3. Bradykinesia Market Trends And Strategies

4. Bradykinesia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Bradykinesia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bradykinesia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bradykinesia Market Growth Rate Analysis
• 5.4. Global Bradykinesia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bradykinesia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bradykinesia Total Addressable Market (TAM)

6. Bradykinesia Market Segmentation

• 6.1. Global Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mono-Therapy
• Combination Therapy
• 6.2. Global Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-Stage Parkinson's
• Advanced-Stage Parkinson's
• 6.3. Global Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bradykinesia
• Tremors
• Rigidity
• 6.4. Global Bradykinesia Market, Sub-Segmentation Of Mono-Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levodopa
• Dopamine Agonists
• MAO-B Inhibitors
• Anticholinergics
• Amantadine
• 6.5. Global Bradykinesia Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levodopa And Carbidopa
• Levodopa And COMT Inhibitors
• Dopamine Agonists And MAO-B Inhibitors
• Levodopa And MAO-B Inhibitors
• Triple Therapy

7. Bradykinesia Market Regional And Country Analysis

• 7.1. Global Bradykinesia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bradykinesia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bradykinesia Market

• 8.1. Asia-Pacific Bradykinesia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bradykinesia Market

• 9.1. China Bradykinesia Market Overview
• 9.2. China Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bradykinesia Market

• 10.1. India Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bradykinesia Market

• 11.1. Japan Bradykinesia Market Overview
• 11.2. Japan Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bradykinesia Market

• 12.1. Australia Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bradykinesia Market

• 13.1. Indonesia Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bradykinesia Market

• 14.1. South Korea Bradykinesia Market Overview
• 14.2. South Korea Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bradykinesia Market

• 15.1. Western Europe Bradykinesia Market Overview
• 15.2. Western Europe Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bradykinesia Market

• 16.1. UK Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bradykinesia Market

• 17.1. Germany Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bradykinesia Market

• 18.1. France Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bradykinesia Market

• 19.1. Italy Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bradykinesia Market

• 20.1. Spain Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bradykinesia Market

• 21.1. Eastern Europe Bradykinesia Market Overview
• 21.2. Eastern Europe Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bradykinesia Market

• 22.1. Russia Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bradykinesia Market

• 23.1. North America Bradykinesia Market Overview
• 23.2. North America Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bradykinesia Market

• 24.1. USA Bradykinesia Market Overview
• 24.2. USA Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bradykinesia Market

• 25.1. Canada Bradykinesia Market Overview
• 25.2. Canada Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bradykinesia Market

• 26.1. South America Bradykinesia Market Overview
• 26.2. South America Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bradykinesia Market

• 27.1. Brazil Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bradykinesia Market

• 28.1. Middle East Bradykinesia Market Overview
• 28.2. Middle East Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bradykinesia Market

• 29.1. Africa Bradykinesia Market Overview
• 29.2. Africa Bradykinesia Market, Segmentation By Combination Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bradykinesia Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bradykinesia Market, Segmentation By Symptom Management, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bradykinesia Market Competitive Landscape And Company Profiles

• 30.1. Bradykinesia Market Competitive Landscape
• 30.2. Bradykinesia Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Medtronic Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Bradykinesia Market Other Major And Innovative Companies

• 31.1. Biogen Inc.
• 31.2. Eisai Co. Ltd.
• 31.3. Kyowa Kirin Co. Ltd.
• 31.4. Lundbeck AS
• 31.5. Amneal Pharmaceuticals Inc.
• 31.6. Orion Corporation
• 31.7. Acadia Pharmaceuticals Inc.
• 31.8. Acorda Therapeutics Inc.
• 31.9. Denali Therapeutics Inc.
• 31.10. Adamas Pharmaceuticals
• 31.11. Impel NeuroPharma
• 31.12. Annovis Bio Inc.
• 31.13. BlueRock Therapeutics LLC
• 31.14. NeuroDerm Ltd.
• 31.15. Cerevance LLC

32. Global Bradykinesia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bradykinesia Market

34. Recent Developments In The Bradykinesia Market

35. Bradykinesia Market High Potential Countries, Segments and Strategies

• 35.1 Bradykinesia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bradykinesia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bradykinesia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료